Researchers Developed New AI Tools for Dementia Risk
The AI-Mind project created two digital tools to identify signs of dementia risk in European citizens.
Updated on Sept. 20, 2026 in Alzheimer’s
Live Poll
Do you trust artificial intelligence to assist doctors in diagnosing early-stage medical conditions?
In early 2026, researchers completed the first phase of the AI-Mind project, which utilized artificial intelligence to analyze dementia risk. The initiative processed 50,000 hours of data from 1,000 European citizens to develop two distinct diagnostic tools.
Why it matters
Earlier detection of dementia allows for more opportunities for monitoring and intervention. Identifying high-risk patients before severe symptoms manifest could potentially extend the time individuals spend without significant cognitive impairment.
The AI-Mind project analyzed 50,000 hours of data from 1,000 European citizens to refine its assessment models. Current global estimates suggest approximately 57 million people live with dementia, with a 7 per cent prevalence among EU citizens over age 60.
The players
AI-Mind project
This is an international research initiative funded by the European Union to advance early detection of dementia through artificial intelligence.
Eli Lilly
This is a global pharmaceutical company collaborating with the AI-Mind researchers on dementia innovation.
Roche
This is a multinational healthcare firm involved in the collaboration to develop tools for brain health.
Bosch
This is a technology and engineering company providing support to the AI-Mind project researchers.
The details
The project introduced the AI-Mind Connector, which identifies specific electrical activity patterns in the brain, and the AI-Mind Predictor, which assesses clinical progression risks using medical history and biological markers. The tools underwent extensive testing in clinical and research settings in Norway throughout the development phase.
Timeline
The first phase of the AI-Mind project concluded in early 2026.
Clinical evaluation for medical approval is expected to be completed by 2035.
Deeper Dive
The project is systematically working to meet the stringent clinical evaluation requirements established by the EU Medical Device Regulation. This development follows a pattern set by modern digital health initiatives that must prove efficacy through long-term clinical data to gain regulatory clearance.
These digital tools aim to eventually provide clinicians with more precise data for early interventions that could alter a patient's care trajectory. While the technology is currently in research and evaluation phases, it signals a future where routine screenings might incorporate AI-driven analysis of brain activity.
The takeaway
Early identification tools represent a shift toward proactive neurological management rather than reactive treatment after symptom onset. Patients and families are encouraged to stay informed about clinical trial developments as diagnostic technologies continue to advance over the next decade.
Further reading
For more information on the evolving landscape of memory care and research, visit Alzheimer’s.
Source note: This article includes information reported by Cyprus Mail.
Live Poll
Do you trust artificial intelligence to assist doctors in diagnosing early-stage medical conditions?
